Related Experiment Videos
Binding parameters of antibodies: pseudo-affinity and other misconceptions
1Center for Molecular Medicine and Immunology, 520 Belleville Avenue, Belleville, NJ, 07109, USA. mjmattes@gscancer.org
Cancer Immunology, Immunotherapy : CII
|January 1, 2005
Summary
Functional affinity is incorrectly used to evaluate monoclonal antibodies (Abs) binding to cell surfaces. This study shows bivalent antibody binding is irreversible, not described by functional affinity, aiding therapeutic antibody development.
Area of Science:
- Immunology
- Biochemistry
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) are crucial in diagnostics and therapeutics.
- Functional affinity is commonly used to assess mAb binding to multivalent antigens, like cell surface receptors.
- Current methods assume mAb-antigen interactions can be simplified to monovalent binding models.
Purpose of the Study:
- To critically evaluate the concept of functional affinity for monoclonal antibodies (mAbs) binding to multivalent antigens.
- To demonstrate the inadequacy of functional affinity in describing complex mAb-antigen interactions.
- To provide a more accurate framework for understanding antibody binding kinetics.
Main Methods:
- Theoretical analysis of antibody-antigen binding kinetics.
- Modeling of bivalent antibody interactions with multivalent cell surface antigens.
- Comparison of functional affinity calculations versus true binding dynamics.
Main Results:
- The concept of functional affinity is demonstrated to be incorrect for multivalent interactions.
- Bivalent antibody binding to cell surfaces often behaves as an irreversible reaction.
- Calculated functional affinity values obscure the actual binding mechanisms and kinetics.
Conclusions:
- Functional affinity is an inappropriate metric for evaluating monoclonal antibody binding to multivalent targets.
- Understanding antibody binding as potentially irreversible is critical for accurate assessment.
- Accurate characterization of antibody-antigen interactions will advance the development of therapeutic antibodies.